$NVLX Nuvilex Appoints CEO and President of Austr
Post# of 63818
Posted On: 03/11/2014 9:10:30 AM
$NVLX Nuvilex Appoints CEO and President of Austrianova to Scientific Advisory Board
Nuvilex Appoints CEO and President of Austrianova to Scientific Advisory Board Dr. Brian Salmons Indispensable for Development of Cannabis-Based Cancer Treatments SILVER SPRING, Md., March 11, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of deadly diseases, announced today that its subsidiary, Medical Marijuana Sciences, Inc., has appointed Brian Salmons, Ph.D., CEO and President of Nuvilex's partner Austrianova, to its Scientific Advisory Board. Dr. Salmons, together with Professor Dr. Walter H. Günzburg, invented and developed the live-cell encapsulation technology now known as Cell-in-a-Box(TM) which has been licensed by Nuvilex for the development of treatments for cancer and diabetes. It is expected that, given his expertise in this and other aspects of the development of disease treatments, Dr. Salmons will play a pivotal role as Medical Marijuana Sciences goes forward with its cannabis-based cancer treatments. Dr. Brian Salmons received his Ph.D. in London. After research positions in the U.S.A., Switzerland and at the Ludwig Maximilian University in Munich, Germany, Dr. Salmons became the Scientific Director of the European biotech/vaccine company, Bavarian Nordic, and was intricately involved in taking the company to an IPO. Bavarian Nordic was sponsor of the Phase1/2 clinical trial in patients with advanced, inoperable pancreatic cancer that involved the use of the combination of live-cell encapsulation and the anti-cancer prodrug ifosfamide. The results of this trial showed that the combination was safe and efficacious. These results were reported in reputable scientific literature and can be viewed by clicking here (please scroll down and click on blue title opposite "121-131"). In 2002, Dr. Salmons co-founded the biotech company, Austrianova, originally a "spin-off" from the Veterinary Medicine University in Vienna. He was instrumental in obtaining orphan drug status from the European Medicines Agency for its lead cell encapsulation product. In 2007, Dr. Salmons co-founded and became the CEO and President of Austrianova Singapore Pte. Ltd., an independent company established in Singapore to further develop the live-cell encapsulation technology as products for a variety of indications such as various forms of cancer, diabetes, neurodegenerative, cardiovascular and infectious diseases. Dr. Salmons is the author or co-author of over 120 peer-reviewed scientific articles and inventor of 8 patent families. Dr. Mark L. Rabe, Chairman of Medical Marijuana Sciences' Scientific Advisory Board, commented, "Dr. Salmons' acceptance of his appointment as a member of the Medical Marijuana Sciences Scientific Advisory Board is a major coup for Nuvilex. His complete knowledge of the Cell-in-a-Box(TM) encapsulation technology, and its many possible applications, will be invaluable as we strive to develop treatments for the deadliest of all cancers employing Cell-in-a-Box(TM) technology in combination with cannabis-based compounds."
http://www.stockwatch.com/News/Item.aspx?bid=...VLX®ion=U
Nuvilex Appoints CEO and President of Austrianova to Scientific Advisory Board Dr. Brian Salmons Indispensable for Development of Cannabis-Based Cancer Treatments SILVER SPRING, Md., March 11, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of deadly diseases, announced today that its subsidiary, Medical Marijuana Sciences, Inc., has appointed Brian Salmons, Ph.D., CEO and President of Nuvilex's partner Austrianova, to its Scientific Advisory Board. Dr. Salmons, together with Professor Dr. Walter H. Günzburg, invented and developed the live-cell encapsulation technology now known as Cell-in-a-Box(TM) which has been licensed by Nuvilex for the development of treatments for cancer and diabetes. It is expected that, given his expertise in this and other aspects of the development of disease treatments, Dr. Salmons will play a pivotal role as Medical Marijuana Sciences goes forward with its cannabis-based cancer treatments. Dr. Brian Salmons received his Ph.D. in London. After research positions in the U.S.A., Switzerland and at the Ludwig Maximilian University in Munich, Germany, Dr. Salmons became the Scientific Director of the European biotech/vaccine company, Bavarian Nordic, and was intricately involved in taking the company to an IPO. Bavarian Nordic was sponsor of the Phase1/2 clinical trial in patients with advanced, inoperable pancreatic cancer that involved the use of the combination of live-cell encapsulation and the anti-cancer prodrug ifosfamide. The results of this trial showed that the combination was safe and efficacious. These results were reported in reputable scientific literature and can be viewed by clicking here (please scroll down and click on blue title opposite "121-131"). In 2002, Dr. Salmons co-founded the biotech company, Austrianova, originally a "spin-off" from the Veterinary Medicine University in Vienna. He was instrumental in obtaining orphan drug status from the European Medicines Agency for its lead cell encapsulation product. In 2007, Dr. Salmons co-founded and became the CEO and President of Austrianova Singapore Pte. Ltd., an independent company established in Singapore to further develop the live-cell encapsulation technology as products for a variety of indications such as various forms of cancer, diabetes, neurodegenerative, cardiovascular and infectious diseases. Dr. Salmons is the author or co-author of over 120 peer-reviewed scientific articles and inventor of 8 patent families. Dr. Mark L. Rabe, Chairman of Medical Marijuana Sciences' Scientific Advisory Board, commented, "Dr. Salmons' acceptance of his appointment as a member of the Medical Marijuana Sciences Scientific Advisory Board is a major coup for Nuvilex. His complete knowledge of the Cell-in-a-Box(TM) encapsulation technology, and its many possible applications, will be invaluable as we strive to develop treatments for the deadliest of all cancers employing Cell-in-a-Box(TM) technology in combination with cannabis-based compounds."
http://www.stockwatch.com/News/Item.aspx?bid=...VLX®ion=U
(0)
(0)